Skip to content
The Nexus
DossierENTITY

tacrolimus

Coverage of tacrolimus in the Nexus archive.

Earliest in view: Jun 5 · 16:55 UTCMost recent: Aug 4 · 11:34 UTC
Co-mentioned in this coverage
hydrochlorothiazidetopic1voriconazoletopic1International Agency for Research on Cancerorganization1high blood pressuretopic1fungal infectionstopic1organ transplant rejectiontopic1MedPage Todayorganization1obinutuzumabtopic1Gazyvatopic1primary membranous nephropathytopic1MAJESTY trialtopic1
Recent coverage
  • HEALTHAug 4 · 11:34 UTCTHE HINDU NATIONAL
    Three common medicines classified as carcinogenic by WHO cancer agency

    The WHO's cancer agency has classified three medicines—hydrochlorothiazide, voriconazole, and tacrolimus—as carcinogenic. Doctors advise against stopping treatments using these drugs for high blood pressure, fungal infections, and organ transplant rejection.

  • HEALTHJun 5 · 16:55 UTCMEDPAGE TODAY
    B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

    The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, according to the global phase III MAJESTY trial. By week 104, 37% of patients achieved remission.

tacrolimus · Dossier · The Nexus